SCHEMBL29630907

SCHEMBL29630907

CC[C@H](C)[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](CC(N)=O)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ ENPEP Q07075 18/20 0.56
▸ ECE1 P42892 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29630547 0.90 ENPEP (0.55) ENPEPECE1
SCHEMBL29630739 0.89 ENPEP (0.54) ENPEPECE1
SCHEMBL31064946 0.88 ENPEP (0.53) ENPEPECE1
SCHEMBL29630867 0.88 ENPEP (0.53) ENPEPECE1
SCHEMBL29630837 0.87 ECE1 (0.57) ENPEPECE1
SCHEMBL29630762 0.87 ECE1 (0.57) ENPEPECE1
SCHEMBL29630811 0.87 ECE1 (0.57) ENPEPECE1
SCHEMBL30122820 0.87 ECE1 (0.57) ENPEPECE1
SCHEMBL30044195 0.87 ECE1 (0.57) ENPEPECE1
SCHEMBL29630557 0.87 ECE1 (0.57) ENPEPECE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230414771-A1 PREPARATION AND USE OF IMMUNOSTIMULATORY CONJUGATED COMPLEXES FOR TARGETED DELIVERY AND ACTIVATION YAFEI SHANGHAI BIOLOGY MEDICINE SCIENCE & TECHNOLOGY CO., LTD. (CN) 2023-12-28 — — US claimed
EP-4108675-A1 PREPARATION AND USE OF IMMUNOSTIMULATORY COUPLING COMPLEX WHICH IS DELIVERED AND ACTIVATED IN TARGETED MANNER Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. (CN) 2022-12-28 — — EP claimed
US-11319341-B2 Immune-stimulating soluble doxorubicin-conjugated complex YAFEI (SHANGHAI) BIOPHARMACEUTICAL CO., LTD. (CN) 2022-05-03 — — US claimed
CN-113274507-B Preparation and use of targeted delivery and activation immunostimulatory conjugate complexes 亚飞(上海)生物医药科技有限公司 2025-02-28 — — CN disclosed
WO-2024132726-A1 SERUM PEPTIDE PATTERNS FOR DIAGNOSTICS OF ACUTE ISCHEMIC STROKE IN HUMANS AND DIFFERENTIAL DIAGNOSIS OF ACUTE ISCHEMIC STROKE FROM INTRACRANIAL HEMORRHAGIC STROKE UNIWERSYTET GDANSKI (PL) 2024-06-27 — — WO disclosed
US-20230414771-A1 PREPARATION AND USE OF IMMUNOSTIMULATORY CONJUGATED COMPLEXES FOR TARGETED DELIVERY AND ACTIVATION YAFEI SHANGHAI BIOLOGY MEDICINE SCIENCE & TECHNOLOGY CO., LTD. (CN) 2023-12-28 — — US disclosed
EP-4108675-A1 PREPARATION AND USE OF IMMUNOSTIMULATORY COUPLING COMPLEX WHICH IS DELIVERED AND ACTIVATED IN TARGETED MANNER Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. (CN) 2022-12-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11319341-B2 Immune-stimulating soluble doxorubicin-conjugated complex TLR3, CD40, TLR6 ENPEP 941/4885ECE1 1561/4885
US-20230414771-A1 PREPARATION AND USE OF IMMUNOSTIMULATORY CONJUGATED COMPLEXES FOR TARGETED DELIVERY AND ACTIVATION CD74, PAICS, MIF ENPEP 2892/4885ECE1 3284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback